Asthika Goonewardene
Stock Analyst at Truist Financial
(3.82)
# 2,152
Out of 4,668 analysts
322
Total ratings
45.4%
Success rate
5.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Reiterated: Buy | $45 → $32 | $29.18 | +8.77% | 5 | Jun 22, 2026 | |
| ACET Adicet Bio | Reiterated: Buy | n/a | $9.38 | - | 14 | Mar 16, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Buy | $10 | $2.10 | +376.19% | 20 | Mar 13, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $155 | $110.89 | +39.78% | 19 | Mar 13, 2026 | |
| LEGN Legend Biotech | Maintained: Buy | $70 | $21.26 | +229.26% | 10 | Mar 13, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | n/a | $211.74 | - | 9 | Mar 9, 2026 | |
| CRBU Caribou Biosciences | Reiterated: Buy | $7 | $1.61 | +334.78% | 11 | Mar 9, 2026 | |
| CGEN Compugen | Reiterated: Buy | $4 | $2.65 | +50.94% | 20 | Mar 3, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $40 | $26.57 | +50.55% | 4 | Mar 3, 2026 | |
| SEPN Septerna | Maintained: Buy | n/a | $40.79 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $29.52 | +1.63% | 22 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $8.99 | - | 28 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $33.41 | +43.67% | 40 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $12.43 | +181.58% | 19 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 | $53.69 | -5.01% | 30 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $2.46 | +225.20% | 25 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $21.16 | - | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $127 → $145 | $143.44 | +1.09% | 12 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $241.30 | n/a | 1 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.43 | n/a | 4 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.767 | n/a | 6 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $15 | $6.25 | n/a | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 262.22 → kr 338.97 | kr 2,141 | n/a | 2 | Jul 14, 2022 |
ArriVent BioPharma
Jun 22, 2026
Reiterated: Buy
Price Target: $45 → $32
Current: $29.18
Upside: +8.77%
Adicet Bio
Mar 16, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.38
Upside: -
Allogene Therapeutics
Mar 13, 2026
Maintained: Buy
Price Target: $10
Current: $2.10
Upside: +376.19%
BioNTech SE
Mar 13, 2026
Maintained: Buy
Price Target: $155
Current: $110.89
Upside: +39.78%
Legend Biotech
Mar 13, 2026
Maintained: Buy
Price Target: $70
Current: $21.26
Upside: +229.26%
Revolution Medicines
Mar 9, 2026
Maintained: Buy
Price Target: n/a
Current: $211.74
Upside: -
Caribou Biosciences
Mar 9, 2026
Reiterated: Buy
Price Target: $7
Current: $1.61
Upside: +334.78%
Compugen
Mar 3, 2026
Reiterated: Buy
Price Target: $4
Current: $2.65
Upside: +50.94%
Zymeworks
Mar 3, 2026
Reiterated: Buy
Price Target: $40
Current: $26.57
Upside: +50.55%
Septerna
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $40.79
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $30
Current: $29.52
Upside: +1.63%
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $8.99
Upside: -
Feb 25, 2026
Reiterated: Buy
Price Target: $48
Current: $33.41
Upside: +43.67%
Feb 24, 2026
Reiterated: Buy
Price Target: $35
Current: $12.43
Upside: +181.58%
Jan 14, 2026
Reiterated: Buy
Price Target: $51
Current: $53.69
Upside: -5.01%
Jan 13, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $2.46
Upside: +225.20%
Nov 11, 2025
Maintained: Buy
Price Target: n/a
Current: $21.16
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $127 → $145
Current: $143.44
Upside: +1.09%
Apr 24, 2024
Maintained: Hold
Price Target: n/a
Current: $241.30
Upside: n/a
Mar 21, 2024
Rated: Hold
Price Target: n/a
Current: $7.43
Upside: n/a
Jan 16, 2024
Rated: Hold
Price Target: n/a
Current: $0.767
Upside: n/a
Aug 23, 2022
Maintained: Buy
Price Target: $19 → $15
Current: $6.25
Upside: n/a
Jul 14, 2022
Maintained: Buy
Price Target: kr 262.22 → kr 338.97
Current: kr 2,141
Upside: n/a